Record-Breaking Price Movement
On 29 May 2026, Venus Remedies Ltd’s stock price surged to Rs.1282.85, setting a fresh 52-week and all-time high. The stock opened with a 5.00% gap up and maintained this level throughout the trading session, reflecting strong investor confidence. This performance outpaced the broader sector by 4.61% and significantly outperformed the Sensex, which recorded a marginal gain of 0.03% on the same day.
The stock has demonstrated a consistent upward trajectory, gaining for five consecutive days and delivering a cumulative return of 24.38% during this period. This momentum is further supported by the stock trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust bullish trend.
Long-Term Outperformance Against Benchmarks
Venus Remedies Ltd’s performance over various time horizons highlights its exceptional growth relative to the broader market. Over the past year, the stock has delivered a staggering 215.27% return, vastly outperforming the Sensex’s decline of 7.04%. Year-to-date, the stock has gained 67.26%, while the Sensex has fallen by 10.95%. The company’s three-year return stands at an impressive 545.78%, dwarfing the Sensex’s 20.75% gain over the same period.
Even over a decade, Venus Remedies Ltd has generated a remarkable 1691.69% return, compared to the Sensex’s 184.72%, illustrating the company’s sustained ability to create shareholder value over the long term.
Financial Strength and Quality Metrics
Venus Remedies Ltd is classified as a micro-cap company with a Mojo Score of 74.0 and a current Mojo Grade of Buy, upgraded from Hold on 12 March 2026. The company’s financial health is underpinned by its net-debt-free status, reflecting a strong balance sheet and prudent capital management.
Operating profit has grown at an annualised rate of 45.72%, while net profit surged by 126.19% in the most recent results announced in March 2026. The company has reported positive results for six consecutive quarters, with quarterly net sales reaching a record Rs.259.40 crores and PBDIT hitting Rs.63.42 crores, both all-time highs.
Return on Capital Employed (ROCE) for the half-year period peaked at 19.85%, and the company maintains a Return on Equity (ROE) of 15.5%, indicating efficient utilisation of shareholder funds. The stock trades at a Price to Book Value of 2.46x, reflecting a fair valuation relative to its peers, supported by a low PEG ratio of 0.09x, which suggests the stock is reasonably priced given its earnings growth.
Valuation and Market Metrics
As of 29 May 2026, Venus Remedies Ltd’s valuation multiples stand at a Price-to-Earnings (P/E) ratio of 16x, EV/EBITDA of 10.47x, and EV/Sales of 2.00x. These metrics indicate a balanced valuation considering the company’s growth trajectory and profitability. The stock’s dividend yield is not available, but it declared a latest dividend of Rs.3 per share, with the last ex-dividend date recorded on 23 September 2013.
The stock’s 52-week trading range spans from Rs.382.85 to Rs.1282.85, with the current price representing a 235.08% premium over the low point, underscoring the significant appreciation in value over the past year.
Technical Analysis Confirms Bullish Momentum
The technical outlook for Venus Remedies Ltd remains strongly bullish. The overall trend shifted to bullish on 12 March 2026 at a price of Rs.927.5, and all key technical indicators, including MACD, Bollinger Bands, KST, Dow Theory, and On-Balance Volume (OBV), signal positive momentum on both weekly and monthly timeframes.
Immediate support is established at the 52-week low of Rs.382.85, while resistance levels at Rs.1002.77 (20-day moving average), Rs.857.76 (100-day moving average), and Rs.703.30 (200-day moving average) have been decisively surpassed. The stock’s ability to sustain above these levels reinforces the strength of the current uptrend.
Delivery volumes have also shown a positive trend, with a 31.81% increase in delivery volume on the day of the price peak compared to the five-day average, indicating strong participation by shareholders.
Quality Assessment Highlights Financial Discipline
Venus Remedies Ltd is rated as an average quality company based on long-term financial performance, with good growth and excellent capital structure. The company maintains a very strong interest coverage ratio of 50.94x and a low average debt to EBITDA ratio of 0.54, reflecting minimal leverage and strong debt servicing capacity.
Notably, the company is net cash positive, with an average net debt to equity ratio of -0.14, and has no promoter share pledging, which supports financial stability. While average ROCE and ROE over five years are modest at 9.53% and 8.61% respectively, recent half-year figures show significant improvement, indicating enhanced operational efficiency.
Recent Financial Trends Reinforce Positive Outlook
The latest quarterly results demonstrate the company’s operational strength, with highest-ever quarterly net sales of Rs.259.40 crores and PBDIT of Rs.63.42 crores. Operating profit margin reached 24.45%, and profit before tax excluding other income stood at Rs.56.66 crores. Quarterly PAT also hit a record Rs.47.50 crores, with earnings per share at Rs.35.53.
Despite a lower cash and cash equivalents balance of Rs.29.61 crores in the half-year period, the company’s overall financial position remains solid, supported by strong profitability and cash flow generation.
Institutional Participation and Market Recognition
Institutional investors have increased their stake by 0.72% over the previous quarter, collectively holding 4% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and growth prospects, given their superior analytical capabilities.
Venus Remedies Ltd has been part of the MomentumNow Stocks list on MarketsMOJO since 2 June 2025, and its Mojo Grade was upgraded to Buy from Hold on 12 March 2026, reflecting improved market sentiment and performance metrics.
Conclusion
The attainment of an all-time high price of Rs.1282.85 by Venus Remedies Ltd marks a significant milestone in the company’s growth journey. Supported by strong financial results, robust technical indicators, and a solid balance sheet, the stock’s performance over multiple timeframes has consistently outpaced market benchmarks. This achievement reflects the company’s sustained operational excellence and disciplined financial management within the Pharmaceuticals & Biotechnology sector.
